Centiva Capital LP Makes New Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Centiva Capital LP acquired a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 3,045 shares of the medical instruments supplier's stock, valued at approximately $281,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Balyasny Asset Management L.P. purchased a new stake in LeMaitre Vascular in the 4th quarter worth approximately $3,090,000. Bank of America Corp DE raised its position in shares of LeMaitre Vascular by 32.8% in the 4th quarter. Bank of America Corp DE now owns 61,752 shares of the medical instruments supplier's stock worth $5,690,000 after acquiring an additional 15,250 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of LeMaitre Vascular by 3.1% in the 4th quarter. BNP Paribas Financial Markets now owns 28,703 shares of the medical instruments supplier's stock worth $2,645,000 after acquiring an additional 874 shares in the last quarter. Freestone Grove Partners LP bought a new position in shares of LeMaitre Vascular in the 4th quarter worth approximately $292,000. Finally, Monashee Investment Management LLC bought a new position in shares of LeMaitre Vascular in the 4th quarter worth approximately $3,686,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Up 1.8%

NASDAQ:LMAT traded up $1.47 on Friday, reaching $84.77. 140,295 shares of the company's stock traded hands, compared to its average volume of 164,599. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The stock has a 50-day simple moving average of $84.19 and a 200-day simple moving average of $92.94. The firm has a market cap of $1.92 billion, a PE ratio of 46.32, a P/E/G ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. During the same period last year, the firm posted $0.44 earnings per share. The company's revenue for the quarter was up 12.0% compared to the same quarter last year. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.94%. LeMaitre Vascular's payout ratio is 40.40%.

Analysts Set New Price Targets

A number of research firms recently weighed in on LMAT. Wells Fargo & Company began coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, LeMaitre Vascular presently has a consensus rating of "Moderate Buy" and an average price target of $98.14.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.79% of the stock is owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.